A- A A+

Pain management in opioid maintenance treatment.

Koller G, Schwarzer A, Halfter K, Soyka M.

Expert Opin Pharmacother. 2019 Aug 16:1-13. doi: 10.1080/14656566.2019.1652270. 

Abstract

https://www.ncbi.nlm.nih.gov/pubmed/31418602

Opioid Addiction, Genetic Susceptibility, and Medical Treatments: A Review.

Wang SC, Chen YC, Lee CH, Cheng CM.

Int J Mol Sci. 2019 Sep 2;20(17). pii: E4294. doi: 10.3390/ijms20174294.

https://www.mdpi.com/1422-0067/20/17/4294/htm

Effects of Parental Opioid Use: Outcomes of Children of Parents in Medication-Assisted Treatment Compared to Healthy Controls.

Betcher HK, Vande Voort JL, Croarkin PE, Gandhi KD, Shekunov J, Larrabee BR, Limbeck MG, Rummans TA, Romanowicz M.

Prim Care Companion CNS Disord. 2019 Aug 15;21(4). pii: 19m02474. doi: 10.4088/PCC.19m02474.

http://www.psychiatrist.com/pcc/article/pages/2019/v21n04/19m02474.aspx

Medication for Opioid Use Disorder After Nonfatal Opioid Overdose and Association With Mortality: A Cohort Study.

Larochelle MR, Bernson D, Land T, Stopka TJ, Wang N, Xuan Z, Bagley SM, Liebschutz JM, Walley AY.

Ann Intern Med. 2018 Aug 7;169(3):137-145. doi: 10.7326/M17-3107. 

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6387681/

Medications for Alcohol and Opioid Use Disorders and Risk of Suicidal Behavior, Accidental Overdoses, and Crime.

Molero Y, Zetterqvist J, Binswanger IA, Hellner C, Larsson H, Fazel S.

Am J Psychiatry. 2018 Oct 1;175(10):970-978. doi: 10.1176/appi.ajp.2018.17101112. 

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169735/

Opioid Use Disorders: Perioperative Management of a Special Population.

Ward EN, Quaye AN, Wilens TE.

Anesth Analg. 2018 Aug;127(2):539-547. doi: 10.1213/ANE.0000000000003477. 

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6523021/

Palliativversorgung von Patienten in Opioidsubstitutionsbehandlung (mit CME)

Hoffmann-Menzel, J.Goldmann, M.Kern, K.Weckbecker, L. Wüllenweber, L. Radbruch

Schmerz 2019 · 33:263–280, doi.org/10.1007/s00482-019-0376-0

Abstract (freier Zugang für 14 Tage möglich)

Korrespondenzadresse: Diese E-Mail-Adresse ist vor Spambots geschützt! Zur Anzeige muss JavaScript eingeschaltet sein!

https://www.springermedizin.de/palliative-schmerztherapie/sucht/palliativversorgung-von-patienten-in-opioidsubstitutionsbehandlu/16728648

Sex differences in high opioid dose escalation among Malaysian patients with long term opioid therapy.

Zin CS, Alias NE, Taufek NH, Ahmad MM.

J Pain Res. 2019 Apr 24;12:1251-1257. doi: 10.2147/JPR.S199243.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6499483/

Buprenorphine and Methadone as Opioid Maintenance Treatments for Heroin-Addicted Patients Induce Oxidative Stress in Blood.

Leventelis C, Goutzourelas N, Kortsinidou A, Spanidis Y, Toulia G, Kampitsi A, Tsitsimpikou C, Stagos D, Veskoukis AS, Kouretas D.

Oxid Med Cell Longev. 2019 Apr 9;2019:9417048. doi: 10.1155/2019/9417048.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6481042/

Concomitant Heroin and Cocaine Use among Opioid-Dependent Patients during Methadone, Buprenorphine or Morphine Opioid Agonist Therapy.

Gastberger S, Baumgartner MR, Soyka M, Quednow BB, Hulka LM, Herdener M, Seifritz E, Mutschler J.

Eur Addict Res. 2019 May 8:1-6. doi: 10.1159/000500542. 

Abstract

https://www.ncbi.nlm.nih.gov/pubmed/31067528

Detection of heroin intake in patients in substitution treatment using oral fluid as specimen for drug testing.

Böttcher M, Lierheimer S, Peschel A, Beck O.

Drug Alcohol Depend. 2019 Mar 23;198:136-139. doi: 10.1016/j.drugalcdep.2019.02.011.

Abstract

https://www.ncbi.nlm.nih.gov/pubmed/30927716

Impact of Substance Use Disorder Pharmacotherapy on Executive Function: A Narrative Review.

Butler K, Le Foll B.

Front Psychiatry. 2019 Mar 1;10:98. doi: 10.3389/fpsyt.2019.00098.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6405638/

Management of Opioid Addiction With Opioid Substitution Treatments: Beyond Methadone and Buprenorphine.

Noble F, Marie N.

Front Psychiatry. 2019 Jan 18;9:742. doi: 10.3389/fpsyt.2018.00742. eCollection 2018. Review.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6345716/

Comparing opium tincture and methadone for medication-assisted treatment of patients with opioid use disorder: Protocol for a multicenter parallel group noninferiority double-blind randomized controlled trial.

Nikoo M, Moazen-Zadeh E, Nikoo N, Javidanbardan S, Kazemi A, Choi F, Vogel M, Gholami A, Tavakoli S, Givaki R, Jazani M, Mohammadian F, Markazi Moghaddam N, Goudarzi N, Schutz C, Jang K, Akhondzadeh S, Krausz M.

Int J Methods Psychiatr Res. 2019 Feb 4:e1768. doi: 10.1002/mpr.1768. 

Abstract

https://www.ncbi.nlm.nih.gov/pubmed/30714249

Measurement-based care using DSM-5 for opioid use disorder: can we make opioid medication treatment more effective?.

Marsden, J., Tai, B., Ali, R., Hu, L., Rush, A. J., and Volkow, N. (2019) 

Addiction, doi.org/10.1111/add.14546.

https://onlinelibrary.wiley.com/doi/10.1111/add.14546

Temperamental Characteristics and Problem-Solving Skills among Patients on Opioid Agonists.

Eslami-Saaraab S, Eslami-Shahrbabaki H, Eslami-Shahrbabaki M, Motaghyan S.

Addict Health. 2018 Jan;10(1):24-31. doi: 10.22122/ahj.v10i1.579.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6312562/

Change in alcohol and other drug use during five years of continuous opioid substitution treatment

Brian Eastwood, John Strang and John Marsden

Drug and Alcohol Dependence, Volume 194, 1 January 2019, Pages 438-446, doi.org/10.1016/j.drugalcdep.2018.11.008

https://www.sciencedirect.com/science/article/pii/S0376871618304897#bib0100

Substitution von A bis Z
Mit der vorliegenden Broschüre möchten wir Ihnen ein Nachschlagewerk an die Hand geben, welches die Grundlagen der Suchttherapie von A bis Z vermittelt und Ihnen daher im Alltag ein hilfreicher Begleiter sein kann. Vor allem Personen, die noch wenig Erfahrung mit der Substitutionsbehandlung haben, sollen unterstützt werden, sich schnell in das Therapiegebiet einzufinden und die Arbeitsabläufe kennen zu lernen. (Hexal, 2018)

https://www.hexal.de/gesundheit/service/serviceartikel/serviceartikel.php?selected_kat=34&kategorie=34

Sanofi Kompendium Substitutionsmedizin – Neuauflage 2018

Das neue Kompendium Substitutionsmedizin bietet allen Ärzten, die in der Praxis mit Suchtmedizin zu tun haben, einen umfassenden Einblick in die verschiedenen Aspekte der Opiatsubstitutionstherapie. Das Kompendium wurde erweitert um die aktuelle Rechtslage und richtet sich auch an ApothekerInnen als zusätzliche Zielgruppe

Das Kompendium kann aufgerufen und runtergeladen werden auf der Substitutionsseite von Sanofi. Die Druckausgabe kann über den Außendienst von Sanofi bestellt werden.

https://www.substitutionsportal.de/

One size does not fit all – evolution of opioid agonist treatments in a naturalistic setting over 23 years.

Nordt, C., Vogel, M., Dey, M., Moldovanyi, A., Beck, T., Berthel, T., Walter, M., Seifritz, E., Dürsteler, K. M., and Herdener, M. (2018) 

Addiction, doi.org/10.1111/add.14442.

Abstract

https://onlinelibrary.wiley.com/doi/10.1111/add.14442

SAMHSA. Medications for opioid use disorder: for healthcare and addiction professionals, policymakers, patients, and families: Treatment Improvement Protocol: TIP 63.

Substance Abuse and Mental Health Services Administration 
[US] Substance Abuse and Mental Health Services Administration, 2018

https://store.samhsa.gov/shin/content/SMA18-5063FULLDOC/SMA18-5063FULLDOC.pdf

Using routinely collected data to understand and predict adverse outcomes in opioid agonist treatment: Protocol for the Opioid Agonist Treatment Safety (OATS) Study.

Larney S, Hickman M, Fiellin DA, Dobbins T, Nielsen S, Jones NR, Mattick RP, Ali R, Degenhardt L.

BMJ Open. 2018 Aug 5;8(8):e025204. doi: 10.1136/bmjopen-2018-025204.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6078240/

Correlates of Long-Term Opioid Abstinence After Randomization to Methadone Versus Buprenorphine/Naloxone in a Multi-Site Trial.

Zhu Y, Evans EA, Mooney LJ, Saxon AJ, Kelleghan A, Yoo C, Hser YI.

J Neuroimmune Pharmacol. 2018 Aug 9. doi: 10.1007/s11481-018-9801-x.

Abstract

https://www.ncbi.nlm.nih.gov/pubmed/30094695

USA. FDA takes new steps to encourage the development of novel medicines for the treatment of opioid use disorder

The U.S. Food and Drug Administration today issued new scientific recommendations aimed at encouraging more widespread innovation and development of novel medication-assisted treatment (MAT) drugs for the treatment of opioid use disorder (OUD). New draft guidance issued today outlines new ways for drug developers to consider measuring and demonstrating the effectiveness and benefits of new or existing MAT products. This new draft guidance is part of the FDA’s ongoing commitment to promote more widespread development, access to and adoption of MAT. (FDA, 06.08.2018)

https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm615892.htm

Pharmacological therapies for management of opium withdrawal.

Rahimi-Movaghar A, Gholami J, Amato L, Hoseinie L, Yousefi-Nooraie R, Amin-Esmaeili M.

Cochrane Database Syst Rev. 2018 Jun 21;6:CD007522. doi: 10.1002/14651858.CD007522.pub2. Review.

Abstract

http://cochranelibrary-wiley.com/doi/10.1002/14651858.CD007522.pub2/abstract;jsessionid=D03C45BCE0AA96B3C23A7429866E7E43.f01t03

Snake Venom Use as a Substitute for Opioids: A Case Report and Review of Literature.

Mehra A, Basu D, Grover S.

Indian J Psychol Med. 2018 May-Jun;40(3):269-271. doi: 10.4103/IJPSYM.IJPSYM_216_17.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5968650/

Continuous opioid substitution treatment over five years: Heroin use trajectories and outcomes.

Eastwood B, Strang J, Marsden J.

Drug Alcohol Depend. 2018 May 16;188:200-208. doi: 10.1016/j.drugalcdep.2018.03.052.

Abstract

https://www.ncbi.nlm.nih.gov/pubmed/29778774

Opioid substitution treatment and heroin dependent adolescents: reductions in heroin use and treatment retention over twelve months.

Smyth BP, Elmusharaf K, Cullen W.

BMC Pediatr. 2018 May 4;18(1):151. doi: 10.1186/s12887-018-1137-4.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5936020/

USA. Lofexidine: FDA approves the first non-opioid treatment for management of opioid withdrawal symptoms in adults

Encouraging more widespread innovation and development of safe and effective treatments for opioid use disorder remains top agency priority. (FDA, USA, 16.05.2018)

https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm607884.htm

Effects of medication assisted treatment (MAT) for opioid use disorder on functional outcomes: A systematic review.

Maglione MA, Raaen L, Chen C, Azhar G, Shahidinia N, Shen M, Maksabedian E, Shanman RM, Newberry S, Hempel S.

J Subst Abuse Treat. 2018 Jun;89:28-51. doi: 10.1016/j.jsat.2018.03.001. Epub 2018 Mar 13.

https://linkinghub.elsevier.com/retrieve/pii/S0740-5472(17)30482-8

  1. Characteristics of opioid-maintained clients smoking fentanyl patches: The importance of confirmatory drug analysis illustrated by a case series and mini-review.
  2. Listening to Patients’ Voices in Developing New Opioid Addiction Treatments.
  3. Alternative Opioid Agonists in the Treatment of Opioid Dependence: A Systematic Review [Internet].
  4. Unsupervised Intake of Medicines for Individuals in Opioid Maintenance [Internet].
  5. Cost-effectiveness of hydromorphone for severe opioid use disorder: findings from the SALOME randomized clinical trial.